| __timestamp | Apellis Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 51796000 |
| Thursday, January 1, 2015 | 13730311 | 72758000 |
| Friday, January 1, 2016 | 22978599 | 61008000 |
| Sunday, January 1, 2017 | 40303878 | 66962000 |
| Monday, January 1, 2018 | 105285576 | 84888000 |
| Tuesday, January 1, 2019 | 220968770 | 107068000 |
| Wednesday, January 1, 2020 | 299921000 | 122964000 |
| Friday, January 1, 2021 | 420869000 | 208808000 |
| Saturday, January 1, 2022 | 387236000 | 253297000 |
| Sunday, January 1, 2023 | 354387000 | 216566000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Apellis Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
From 2014 to 2023, Apellis Pharmaceuticals increased its R&D budget by an impressive 4,100%, peaking in 2021. This surge underscores their aggressive pursuit of groundbreaking therapies. Meanwhile, BioCryst Pharmaceuticals also ramped up its R&D spending by approximately 320% during the same period, with a notable peak in 2022.
These investments highlight the strategic focus of both companies on developing innovative treatments. As the biotech industry continues to evolve, such financial commitments are essential for maintaining a competitive edge and delivering life-changing solutions.
Comparing Innovation Spending: Novo Nordisk A/S and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: AbbVie Inc. vs BioCryst Pharmaceuticals, Inc.
R&D Insights: How Novartis AG and Apellis Pharmaceuticals, Inc. Allocate Funds
Research and Development Expenses Breakdown: Teva Pharmaceutical Industries Limited vs Apellis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Genmab A/S and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Summit Therapeutics Inc. or Apellis Pharmaceuticals, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and BioCryst Pharmaceuticals, Inc.
R&D Insights: How Apellis Pharmaceuticals, Inc. and Soleno Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Apellis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: Travere Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.